Mesothelioma Clinical Trial Involves Immunotherapy Before Surgery

Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll at least 30 patients for the study. Principal investigator Dr. Patrick Forde Forde, a thoracic oncologist at Johns Hopkins, spoke about the study to several patients and patient advocates in a conference call orchestrated by the Mesothelioma Applied Research Foundation in Washington, D.C. “The study is building on work already done for other cancers,” Forde said. “Initial results in other cancers, such as breast and lung cancer, have been promising with this approach.” Yervoy Delivered Just Once in Clinical Trial The study wants 15 patients receiving Opdivo before surgery and another 15 taking Opdivo and Yervoy. Opdivo will be given 42, 28 and 14 days before surgery. Yervoy will be administered just once, on day 42. The study also allows for patients to continue receiving regular immunotherapy treatments after surgery for up to one yea...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Conditions:   Thoracic Cancer;   Non-small Cell Lung Cancer;   Small-cell Lung Cancer;   Pleural Mesothelioma Intervention:   Other: eRAPID online symptom monitoring in lung cancer Sponsors:   University of Leeds;   The Leeds Teaching Hospitals NHS Trust;   Iqvia Pty Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Raw asbestos imported to the United States dropped significantly in 2019, according to the recently released U.S. Geological Survey Mineral Commodity Summaries report. The U.S. imported an estimated 100 metric tons of asbestos last year. It’s the smallest amount since records were first kept in 1910, long before the mineral became a major part of the construction industry in America. That number is in sharp contrast to the 681 metric tons imported in 2018. All imported asbestos went to the chloralkali industry — for the second consecutive year — to use in the manufacturing of semipermeable diaphragms for ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsThis study indicated that CT ‐707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose‐expansion phase recruitment has started.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
The U.S. Food and Drug Administration found asbestos-contaminated talc in nine of the 52 cosmetic products tested during its year-long study released this week. The products with asbestos were recalled at various times throughout the past year when individual results were obtained and the public was notified. Monday’s announcement by the FDA was labeled a Constituent Update and Final Report. It also included those products that showed no trace of contamination. AMA Analytical Services Inc. in Lanham, Maryland, performed all testing for the FDA, using polarized light microscopy and transmission electron microscopy, cu...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSION: In this contest, MacroH2A.1 overexpression supports its function as an epigenetic stabilizer that helps to establish and maintain differentiated states. PMID: 32077824 [PubMed - as supplied by publisher]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at Asbestos.com. “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is highly aggressive neoplasm, with a median survival of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The U.S. Food and Drug Administration moved closer on Tuesday to formulating standardized testing of talc-based products for the presence of toxic asbestos fibers. Experts from eight different federal agencies explained earlier recommendations at a day-long hearing. The session also featured input from 25 members of the public, which included industry representatives, consumer advocates and testing experts. “Standards are needed,” said Dr. Paul Howard, FDA Office of Regulatory Science, during his presentation. “They just don’t exist at this time.” Dr. Linda Katz, director of the FDA Office of ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Conferences | Environmental Health | Food and Drug Administration (FDA) | France Health | Immunotherapy | John Hopkins University | Lung Cancer | Mesothelioma | Netherlands Health | Radiation Therapy | Study | Texas University | University of Maryland | Yervoy